Expert Interview
A Second Look: Discussing the recent results from the phase 3 KEYNOTE-A18 trial, studying Merck's Keytruda in combination with EBRT and chemotherapy followed by brachytherapy, for patients with cervical cancer.
Ticker(s): MRKInstitution: Kaiser Permanente
- Gynecologist oncologist at Kaiser Permanente Riverside Medical Center (CA).
- Currently treats 10 patients with HER2-expressing advanced solid tumors and treats 75 patients with ovarian cancer and has 2 patients on Elahere.
- Very familar with data presented at the ASCO 2023 presentation on AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
